Platelet transfusions are commonly used to prevent bleeding in preterm infants with thrombocytopenia. Data are lacking to provide guidance regarding thresholds for prophylactic platelet transfusions ...

A newborn infant with isoimmune thrombocytopenic purpura due to incompatibility of the P1 A1 platelet antigen system was treated with transfusion of incompatible platelets and by exchange transfusion, ...

Neonatal alloimmune thrombocytopenia is a rare but potentially life threatening condition in newborns. It can cause bleeding in the brain and long-term effects. Treatment usually involves a platelet ...

There is a lack of evidence-based guidelines for neonatal transfusion practices as seen by the diverse RBC transfusion practices among individuals and institutions. [3,5,27,28,29,30,31,32] The US ...

While thrombocytopenia and bleeding are events that often occur together in neonates, this may not signify cause and effect. In fact, one study reported that 91% of neonates with low platelet counts ...

Abstract and Introduction Review of Normal Platelet Physiology and Megakaryocytopoisis Qualitative Platelet Abnormalities Conclusion References Nitric oxide (NO) is another drug used in the neonatal ...

Neonatal alloimmune thrombocytopenia (NAIT) is a disorder that affects pregnant people and their fetuses. It occurs when the birthing parent’s immune system produces antibodies that attack and destroy ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from ...

-- Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT -- -- In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a ...